TABLE 2.
Comparison of genetic status in the primary tumor, PDX tumor, and the SBA cell line
| Genetic status | Primary tumor | PDX | Cell line |
|---|---|---|---|
| Microsatellite status | MSS | MSS | MSS |
| Mutation frequency in CSF1R, FGFR3, FLT3, HRAS, RET, PDGFRA | 100% | 100% | 100% |
| Mutation frequency in APC | 48% | 100% | 100% |
| Mutation frequency in TP53 | 46.2% | 100% | 100% |
| Mutation frequency in ALK | 52.8% | 69% | 61.5% |
| Mutation frequency in EGFR | 51.1% | 51% | 53.9% |
| Mutation frequency in KDR | 46.7% | 46.2% | 47% |
| Mutation frequency in KDR | 50.8% | 50.5% | 48.8% |
| Mutation frequency in KDR | 60.5% | 61.6% | 60% |
| Mutation frequency in KRAS | (−) | 100% | 100% |
| Mutation frequency in TP53 | (−) | 15% | 25% |
| Mutation in ERBB4, FBXW7, KRAS IDH2, NOTCH1, PTEN, SMARCB1, STK11 | (−) | (+) | (−) |
Percentage indicates the mutation rate in indicated gene.
Abbreviations: PDX, patient‐derived xenograft; MSS, microsatellite stable.